Alnylam Pharma (ALNY) Stock Forecast & Price Target
ALNY Analyst Ratings
Moderate Buy
17Buy8Hold0Sell
Based on 25 analysts giving stock ratings to Alnylam Pharma in the past 3 months
ALNY Stock 12 Month Forecast
Average Price Target
MXN 5,984.20▲(86.93% Upside)Based on 25 Wall Street analysts offering 12 month price targets for Alnylam Pharma in the last 3 months. The average price target is MXN 5,984.20 with a high forecast of MXN 8,550.38 and a low forecast of MXN 4,134.25. The average price target represents a 86.93% change from the last price of MXN 3,201.29.
Past 12 Months12 Month ForecastJan2026Oct2026
HighMXN 8.55K
AverageMXN 5.98K
LowMXN 4.13K
Highest Price TargetHighestMXN 8,550.38Average Price TargetMXN 5,984.20Lowest Price TargetLowestMXN 4,134.25
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Eliana Merle | Barclays | MXN 8,456.42→MXN 7,140.98 | buy | 123.07%Upside | Reiterated | 11/02/26 | ||
| Danielle Brill | Truist Financial | MXN 5,919.49→MXN 4,228.21 | hold | 32.08%Upside | Downgraded | 11/02/26 | ||
| Whitney Ijem | Canaccord Genuity | MXN 8,061.79→MXN 6,069.83 | buy | 89.61%Upside | Reiterated | 11/02/26 | ||
| Patrick Trucchio | H.C. Wainwright | MXN 8,550.38 | buy | 167.09%Upside | Reiterated | 10/30/26 | ||
| Keay Nakae | Chardan Capital | MXN 7,986.62→MXN 7,047.02 | buy | 120.13%Upside | Reiterated | 10/30/26 | ||
| Martin Auster | Raymond James | MXN 7,892.66→MXN 5,919.49 | buy | 84.91%Upside | Reiterated | 10/30/26 | ||
| Edward Tenthoff | Piper Sandler | MXN 9,189.31→MXN 7,704.74 | buy | 140.68%Upside | Reiterated | 10/30/26 | ||
| Joon Lee | UBS | MXN 6,652.38→MXN 6,182.58 | buy | 93.13%Upside | Reiterated | 10/30/26 | ||
| William Pickering | Bernstein | ― | hold | ― | Downgraded | 10/30/26 | ||
| Salveen Richter | Goldman Sachs | MXN 10,072.54→MXN 6,013.46 | buy | 87.84%Upside | Reiterated | 10/30/26 | ||
| Michael Ulz | Morgan Stanley | MXN 5,637.61→MXN 4,510.09 | hold | 40.88%Upside | Assigned | 10/30/26 | ||
| Ritu Baral | TD Cowen | MXN 9,057.77→MXN 6,652.38 | buy | 107.80%Upside | Assigned | 10/30/26 | ||
| Ilya Zubkov | Freedom Capital Markets | MXN 7,704.74→MXN 6,577.22 | buy | 105.46%Upside | Reiterated | 10/30/26 | ||
 Unknown AnalystNot Ranked | Guggenheim | ― | hold | ― | Reiterated | 10/29/26 | ||
| Faisal Khurshid | Jefferies | MXN 4,885.93→MXN 4,698.01 | hold | 46.75%Upside | Reiterated | 10/29/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Eliana Merle | 11/02/26 | MXN 8,456.42→MXN 7,140.98 | buy | 123.07%Upside | Reiterated | Barclays | ||
| Danielle Brill | 11/02/26 | MXN 5,919.49→MXN 4,228.21 | hold | 32.08%Upside | Downgraded | Truist Financial | ||
| Whitney Ijem | 11/02/26 | MXN 8,061.79→MXN 6,069.83 | buy | 89.61%Upside | Reiterated | Canaccord Genuity | ||
| Patrick Trucchio | 10/30/26 | MXN 8,550.38 | buy | 167.09%Upside | Reiterated | H.C. Wainwright | ||
| Keay Nakae | 10/30/26 | MXN 7,986.62→MXN 7,047.02 | buy | 120.13%Upside | Reiterated | Chardan Capital | ||
| Martin Auster | 10/30/26 | MXN 7,892.66→MXN 5,919.49 | buy | 84.91%Upside | Reiterated | Raymond James | ||
| Edward Tenthoff | 10/30/26 | MXN 9,189.31→MXN 7,704.74 | buy | 140.68%Upside | Reiterated | Piper Sandler | ||
| Joon Lee | 10/30/26 | MXN 6,652.38→MXN 6,182.58 | buy | 93.13%Upside | Reiterated | UBS | ||
| William Pickering | 10/30/26 | ― | hold | ― | Downgraded | Bernstein | ||
| Salveen Richter | 10/30/26 | MXN 10,072.54→MXN 6,013.46 | buy | 87.84%Upside | Reiterated | Goldman Sachs | ||
| Michael Ulz | 10/30/26 | MXN 5,637.61→MXN 4,510.09 | hold | 40.88%Upside | Assigned | Morgan Stanley | ||
| Ritu Baral | 10/30/26 | MXN 9,057.77→MXN 6,652.38 | buy | 107.80%Upside | Assigned | TD Cowen | ||
| Ilya Zubkov | 10/30/26 | MXN 7,704.74→MXN 6,577.22 | buy | 105.46%Upside | Reiterated | Freedom Capital Markets | ||
| Unknown AnalystNot Ranked | 10/29/26 | ― | hold | ― | Reiterated | Guggenheim | ||
| Faisal Khurshid | 10/29/26 | MXN 4,885.93→MXN 4,698.01 | hold | 46.75%Upside | Reiterated | Jefferies |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Alnylam Pharma
3 Months
Success Rate24/40 ratings generated profit
60%
Average Return
+5.33%
Copying Keay Nakae's trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +5.33% per trade.
1 Year
Success Rate19/29 ratings generated profit
66%
Average Return
+18.62%
Copying Whitney Ijem's trades and holding each position for 1 Year would result in 65.52% of your transactions generating a profit, with an average return of +18.62% per trade.
2 Years
Success Rate27/40 ratings generated profit
68%
Average Return
+27.51%
Copying Keay Nakae's trades and holding each position for 2 Years would result in 67.50% of your transactions generating a profit, with an average return of +27.51% per trade.
ALNY Analyst Recommendation Trends
| Rating | Jun 26 | Jul 26 | Aug 26 | Sep 26 | Oct 26 |
|---|---|---|---|---|---|
| Strong Buy | 34 | 35 | 29 | 27 | 21 |
| Buy | 19 | 23 | 24 | 20 | 10 |
| Hold | 10 | 9 | 9 | 14 | 13 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 63 | 67 | 62 | 61 | 44 |
In the current month, ALNY has received 31 Buy Ratings, 13 Hold Ratings, and 0 Sell Ratings. ALNY average Analyst price target in the past 3 months is 5,984.20.
ALNY Financial Forecast
HighMXN 49.28
ConsensusMXN 32.97
LowMXN 10.76
ALNY Earnings Forecast
Next quarter’s earnings estimate for ALNY is MXN 32.97 with a range of MXN 10.76 to MXN 49.28. The previous quarter’s EPS was MXN 296.83. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
HighMXN 30.8B
ConsensusMXN 28.8B
LowMXN 27.4B
ALNY Sales Forecast
Next quarter’s sales forecast for ALNY is MXN 28.83B with a range of MXN 27.44B to MXN 30.75B. The previous quarter’s sales results were MXN 27.53B. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
ALNY Stock Forecast FAQ
What is MX:ALNY’s average 12-month price target, according to analysts?
Based on analyst ratings, Alnylam Pharma’s 12-month average price target is Mex$5,984.20.
What is MX:ALNY’s upside potential, based on the analysts’ average price target?
Alnylam Pharma has 86.93% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Alnylam Pharma a Buy, Sell or Hold?
Alnylam Pharma has a consensus rating of Moderate Buy, which is based on 17 buy ratings, 8 hold ratings and 0 sell ratings.
What is Alnylam Pharma’s share price target?
The average share price target for Alnylam Pharma is Mex$5,984.20. This is based on 25 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is Mex$8,550.38, and the lowest forecast is Mex$4,134.25. The average share price target represents a 86.93% increase from the current price of Mex$3,201.29.
What do analysts say about Alnylam Pharma?
Alnylam Pharma’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 25 Wall Street analysts.
How can I buy shares of Alnylam Pharma?
To buy shares of MX:ALNY, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
